, Volume 5, Issue 4, pp 497–498 | Cite as

New treatments for neuromuscular disease: Optimism and obstacles

  • Hanns Lochmüller
  • Robert C. Griggs


  1. 1.
    Müller JS, Mihaylova V, Abicht A, Lochmüller H. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 2007;9: 1–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Thirion C, Lochmüller H. Current status of gene therapy for muscle diseases. Drug News Perspect 2007;20: 357–363.PubMedCrossRefGoogle Scholar
  3. 3.
    Rifai Z, Welle S, Moxley RT, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 1995;268: E67-E74.PubMedGoogle Scholar
  4. 4.
    Treatment of neuromuscular diseases. In: Griggs RC, Moxley RT, editors. Advances in neurology, vol. 17. New York: Raven Press; 1977.Google Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2008

Authors and Affiliations

  • Hanns Lochmüller
    • 1
  • Robert C. Griggs
    • 2
  1. 1.Institute of Human GeneticsUniversity of NewcastleNewcastle upon TyneUK
  2. 2.Muscle Study Group Executive CommitteeUniversity of Rochester School of Medicine and DentistryRochesterNew York

Personalised recommendations